Immatics N.V.

Industry

  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Drug Discovery Technologies
      • Bioinformatics
      • Genomics-Proteomics
    • Large Molecule
    • Gene Therapy, Cell Therapy

Other Names/Subsidiaries

  • Immatics Biotechnologies GmbH
  • Immatics US
See more in Biomedtracker

Latest on Immatics N.V.

In Vivo

TechBio Investment Snapshot: Funding, Alliances And Collaboration

 
• By Jo Shorthouse

The number of financings among life sciences companies in the TechBio sector increased from Q3 2023, stabilizing in H1 2024. During the period Q3 2023 – Q3 2024, a total of $6bn was raised, with the s

Scrip

Deal Watch: Merck Decides Better Late Than Never In GLP-1 Deal With Hansoh

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Merck Obtains Global Rights To Hansoh’

Scrip

Finance Watch: 2024 Has Now Beaten 2023’s Total Of 21 IPOs

 
• By Mandy Jackson

The number of biopharmaceutical companies that have gone public in the US in 2024 has now beat the 2023 total of 21 with the 10 October initial public offerings by Upstream Bio Inc. and CAMP4 Thera

Scrip

Immatics Off To Phase III With IMA203 After Positive Melanoma Results

 
• By Alaric DeArment

Immatics N.V. ’s lead T-cell receptor (TCR) therapy candidate, IMA203, is two months away from entering Phase III development as the company announced positive Phase Ib data in metastatic melanoma. Th